MannKind Corporation has announced the appointment of Patrick McCauley as Chief Commercial Officer, effective immediately. McCauley was most recently Area VP, West US, Urulogy/PCP Sales for Astellas Pharma and had served in various sales and compliance positions with Astellas for the past dozen years. He had previously worked for Yamanouchi Pharma America, Bristol-Myers Squibb, and DuPont Pharmaceuticals.
Earlier this year, the company announced that it was expanding its sales force for Afrezza inhaled insulin, which it began distributing in the US in 2016 after Sanofi returned rights to the product.
MannKind’s previous Chief Commercial Officer, Michael Castagna, who was recently appointed as CEO, commented, “Pat is an exceptional addition to our executive leadership team and he will be a huge asset for us as we transform MannKind into a world class company. I expect Pat will help us to accelerate the growth of Afrezza and pipeline products to come, and position our company to deliver strong results in the years ahead.”
McCauley said, “MannKind’s future is undoubtedly bright and I am thrilled to be a part of the company. Afrezza is an innovative product with the attributes that I believe can provide benefits to patients battling diabetes in this unfortunately large area of unmet medical need.”
Read the MannKind press release.
